Survey Shows 65% of Affected Americans Want Access to Psychedelic Treatments for Mental Health Conditions

Video

Data have shown that patients with treatment-resistant anxiety, depression, and post-traumatic stress disorder are among those who would benefit from an expanded treatment offering that would include psychedelic medicines.

Pharmacy Times interviewed Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, on the implications of a survey that showed 65% of affected Americans want access to psychedelics for the treatment of mental health conditions.

Specifically, data have shown that patients with treatment-resistant anxiety, depression, and post-traumatic stress disorder (PTSD) are among those who would benefit from an expanded therapeutic regimen that includes psychedelic medicines, which have been found to be both effective and safe in the treatment of these conditions.

During the discussion, Marques explained how treatment-resistant depression, anxiety, and PTSD are currently defined, how psychedelic medicine works differently than other current treatments on the market for these conditions, and why there has been increased attention recently on psychedelic medicine for these conditions rather than further investigation into other less potentially controversial pharmaceutical treatments.

Related Videos
Pride flags during pride event -- Image credit: ink drop | stock.adobe.com
Female Pharmacist Holding Tablet PC - Image credit: Tyler Olson | stock.adobe.com
African American male pharmacist using digital tablet during inventory in pharmacy - Image credit: sofiko14 | stock.adobe.com
Young woman using smart phone,Social media concept. - Image credit: Urupong | stock.adobe.com
Pharmacy Times Public Health Matters Podcast (logo)
selling mental health medication to man at pharmacy | Image Credit: Syda Productions - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Therapy session -- Image credit: pressmaster | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.